Ramesh Gowda, MD
Interventional Cardiology · New York, NYNPI 1073589636
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Shockwave Medical, Inc at 48.3% of the total. Reporting peaked in 2024 at $33,332 and has fallen 52.8% since, to $15,729 in 2025. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,113 payments — averaging $116.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$63K
- Bard Peripheral Vascular, Inc.$17K
- Inari Medical, Inc.$9K
- Boston Scientific$7K
- Penumbra, Inc.$4K
- Angiodynamics, Inc.$4K
- plus $26K from 42 others
Across 1 payment — averaging $1700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bard Peripheral Vascular, Inc.$2K
What the payments were for
- Consulting fees$15,18512%
- Speaking & faculty fees$43,25033%
- Travel & lodging$12,1759%
- Food & beverage$58,52145%
- Education$5450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$45,361
- Vascular Lithotripsy$12,541
- FLOWTRIEVER CATHETER, S$8,746
- CT THROMBECTOMY SYSTEM KIT$8,746
- LUTONIX$4,264
- Indigo System$3,679
- Auryon Laser System 100-120 Vac$3,569
- VENOVO$2,287
- IGT D Peripheral$1,593
- Torus Stent Graft System$1,424
- ENDOCROSS Device$1,424
- Abre$1,230
- 2CM PERIPHERAL CUTTING BALLOON$1,071
- DRAGONFLY OPSTAR$981
- JARDIANCE$975
- Lutonix Drug Coated Balloon$957
- Venclose Maven Catheter$852
- Zilver 635$771
- CLOTTRIEVER BOLD CATHETER$751
- Impella$583
How this compares
$129,676 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 239 | $250,774 |
| EntrestoSacubitril/Valsartan | 125 | $139,189 |
| XareltoRivaroxaban | 109 | $102,537 |
| Repatha SureclickEvolocumab | 81 | $89,798 |
| BrilintaTicagrelor | 48 | $53,304 |
| JardianceEmpagliflozin | 41 | $41,750 |
| FarxigaDapagliflozin Propanediol | 31 | $39,455 |
| VascepaIcosapent Ethyl | 52 | $29,785 |
| VerquvoVericiguat | 14 | $12,955 |
| Praluent PenAlirocumab | 12 | $10,307 |
| Rosuvastatin Calcium | 533 | $7,052 |
| ClopidogrelClopidogrel Bisulfate | 621 | $6,666 |
| Atorvastatin Calcium | 563 | $6,594 |
| Ezetimibe | 243 | $6,159 |
| Metoprolol Succinate | 422 | $5,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $201 | $250,774239 claims |
| NovartisEntresto | $499 | $139,189125 claims |
| Johnson & JohnsonXarelto | $137 | $102,537109 claims |
| AstraZenecaBrilinta, Farxiga | $171 | $92,75979 claims |
| Boehringer IngelheimJardiance | $1,054 | $41,75041 claims |
| MerckVerquvo | $363 | $12,95514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.